Novel NK- & T Cell-Based Therapy Programs for Multiple Myeloma
ORLANDO— Data introducing an extensive platform in genetically-modified NK- and T cell-based programs, and highlighting long-term safety and efficacy results from the phase I study of PNK-007 in patients with multiple myeloma, were announced at the 2019 ASH Annual Meeting.
In pre-clinical studies, an allogeneic, placental-derived CD19 CAR T cell-based product candidate demonstrated in vivo anti-tumor efficacy in a lymphoma tumor model. Additionally, the a CD38 CAR NK cell-based product candidate showed in vitro and in vivo anti-tumor activity against CD38+ lymphoma and multiple myeloma cell lines without any on-target, off-tumor effect.
Moreover, an allogeneic, placental CD34+ cell-derived NK product candidate overexpressing a CD16 variant demonstrated its versatile combination potential with monoclonal antibodies to elicit in vitro and in vivo enhanced antibody-dependent cell mediated cytotoxicity (ADCC) function against lymphoma cell lines.
Results from a phase I clinical study evaluating PNK-007 in patients with multiple myeloma demonstrated a single infusion of PNK-007 was well-tolerated after autologous stem cell transplant for up to 1 year. PNK-007 is a first-generation investigational allogeneic off-the-shelf NK cell therapy. No serious adverse events were attributable to PNK‐007, and no dose-limiting toxicity, graft-verse-host disease, cytokine release syndrome, graft failure or graft rejection was observed.
PNK‐007 is an allogeneic, off-the-shelf NK cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers and solid tumors. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive immunity. When derived from the placenta, these cells offer intrinsic safety and versatility, allowing potential use across a range of organs and tissues. PNK cells are currently being investigated as a treatment for acute myeloid leukemia and multiple myeloma.